PL2731597T3 - Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych - Google Patents

Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych

Info

Publication number
PL2731597T3
PL2731597T3 PL12811030.1T PL12811030T PL2731597T3 PL 2731597 T3 PL2731597 T3 PL 2731597T3 PL 12811030 T PL12811030 T PL 12811030T PL 2731597 T3 PL2731597 T3 PL 2731597T3
Authority
PL
Poland
Prior art keywords
skavengers
ketoaldehyde
hypertension
gamma
methods
Prior art date
Application number
PL12811030.1T
Other languages
English (en)
Inventor
L. Jackson Roberts
Venkataraman Amarnath
David G. Harrison
Annet Kirabo
Original Assignee
Vanderbilt University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vanderbilt University filed Critical Vanderbilt University
Publication of PL2731597T3 publication Critical patent/PL2731597T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/58Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL12811030.1T 2011-07-12 2012-07-12 Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych PL2731597T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506848P 2011-07-12 2011-07-12
PCT/US2012/046549 WO2013010034A2 (en) 2011-07-12 2012-07-12 Methods for treating inflammation and hypertension with gamma-ketoaldehyde skavengers

Publications (1)

Publication Number Publication Date
PL2731597T3 true PL2731597T3 (pl) 2024-04-29

Family

ID=47506934

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12811030.1T PL2731597T3 (pl) 2011-07-12 2012-07-12 Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych

Country Status (13)

Country Link
US (4) US10975033B2 (pl)
EP (1) EP2731597B1 (pl)
JP (1) JP6280033B2 (pl)
KR (2) KR102050700B1 (pl)
CN (2) CN111494352A (pl)
AU (1) AU2012281061B2 (pl)
BR (1) BR112014000810A8 (pl)
CA (1) CA2844150C (pl)
ES (1) ES2970814T3 (pl)
HU (1) HUE065757T2 (pl)
MX (1) MX383365B (pl)
PL (1) PL2731597T3 (pl)
WO (1) WO2013010034A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130018478A (ko) * 2011-08-09 2013-02-25 주식회사 엘지화학 신규한 구조의 이차전지 팩
US10166248B1 (en) 2015-12-21 2019-01-01 Vanderbilt University Methods of preventing platelet activation
US11400103B2 (en) 2015-12-21 2022-08-02 Vanderbilt University Methods of preventing platelet activation
BR112019000216B1 (pt) * 2016-07-06 2023-04-18 Vanderbilt University Usos de removedores de gama-cetoaldeídos reativos para tratar dano oxidante celular relacionado à idade por deficiência de sirtuína, para preservar a sirtuína e para promover a sobrevivência de pelo menos uma célula eucariótica pela preservação da atividade de desacetilação mediada por sirtuína
US20190247375A1 (en) * 2016-07-07 2019-08-15 Vanderbilt University Prevention And Treatment Of Atrial Fibrillation/Flutter With Gamma-Ketoaldehyde Scavengers
JP7189127B2 (ja) * 2016-09-06 2022-12-13 メタボリック・テクノロジーズ,インコーポレーテッド 非アルコール性脂肪性肝疾患(nafld)、nash、aldまたは肝臓に関する状態の治療、予防または改善のためのガンマ-ケトアルデヒドスカベンジャーの組成物および使用方法
EP3865136A1 (en) 2016-09-07 2021-08-18 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for corona virus treatment
EP3541185B1 (en) * 2016-11-15 2024-04-24 Vanderbilt University Use of 2-hydroxybenzylamine in the treatment and prevention of pulmonary hypertension
MX2019012659A (es) * 2017-04-27 2020-07-24 Univ Vanderbilt Metodos para tratar ateroesclerosis con neutralizadores gamma-cetoaldehido.
EP3678650A4 (en) * 2017-09-05 2021-05-19 MTI Biotech, Inc. COMPOSITIONS AND METHODS OF USING GAMMA KETOALDHEYD SCAVENGERS TO TREAT, PREVENT, OR IMPROVE LIVER FIBROSIS
US20210023032A1 (en) * 2017-09-05 2021-01-28 Mti Biotech, Inc. Compositions and methods of use of gamma-ketoaldheyde scavengers for treating, preventing or improving fibrosis of the liver
CN109836341B (zh) * 2017-11-28 2021-08-27 江阴技源药业有限公司 一种水杨胺醋酸盐的制备方法
US20200197323A1 (en) * 2018-12-21 2020-06-25 Vanderbilt University Methods for suppressing accumulation of reflux-induced protein adducts
EP4097115A4 (en) * 2020-01-27 2024-03-13 Vanderbilt University ANTI-MITOCHONDRIAL ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF
CN118652245B (zh) * 2024-08-21 2024-11-12 首都医科大学附属北京儿童医院 一种化合物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740439A (en) * 1968-06-24 1973-06-19 Ciba Geigy Corp Treating hypertension with beta-aminoalkane carboxylic acids
US3794734A (en) 1971-03-03 1974-02-26 Merck & Co Inc Methods of treating edema and hypertension using certain 2-aminoethylphenols
US4123537A (en) * 1977-05-26 1978-10-31 Merck & Co., Inc. 2-Halo-4-aminomethyl-6-alkyl-3-pyridinols useful as diuretics in treating hypertension and edema
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
EP0839799A4 (en) 1995-05-19 1998-07-29 Kissei Pharmaceutical 2-HYDROXYPHENYLALKYLAMINE DERIVATIVES AND MAILLARD REACTION INHIBITORS
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
DE60121794D1 (de) * 2000-11-02 2006-09-07 Univ South Carolina Verwendung von pyridoxamin für die behandlung und unterdrückung von komplikationen im zusammenhang mit adipositas
US6824786B2 (en) * 2001-11-27 2004-11-30 Ruey J. Yu Compositions comprising phenyl-glycine derivatives
US7705054B1 (en) 2004-10-20 2010-04-27 Vanderbilt University Method of preventing and/or treating oxidant injury in neurodegenerative and oxidative diseases
EP2656850B1 (en) * 2007-10-05 2016-07-27 InDex Pharmaceuticals AB Oligonucleotides for the treatment or alleviation of edema
KR100973343B1 (ko) * 2008-02-01 2010-07-30 롯데칠성음료주식회사 기호성이 우수한 혼합차 조성물 및 그 제조방법
CN101305759B (zh) * 2008-06-19 2011-09-07 成都大学 一种苦荞保健茶及其制备方法
CN101843671A (zh) * 2009-03-25 2010-09-29 王文祥 苦荞托毒丸及其制备方法
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
CN101606986A (zh) * 2009-07-29 2009-12-23 李钢 一种具有降糖作用的组合物及其药物

Also Published As

Publication number Publication date
BR112014000810A8 (pt) 2022-11-29
US10975033B2 (en) 2021-04-13
MX2014000515A (es) 2014-03-27
AU2012281061B2 (en) 2017-08-03
AU2012281061A1 (en) 2014-02-20
MX383365B (es) 2025-03-13
KR102050700B1 (ko) 2019-11-29
WO2013010034A3 (en) 2013-03-28
CN103796648A (zh) 2014-05-14
BR112014000810A2 (pt) 2017-06-13
ES2970814T3 (es) 2024-05-30
US20250034093A1 (en) 2025-01-30
JP6280033B2 (ja) 2018-02-14
CN103796648B (zh) 2019-10-25
CN111494352A (zh) 2020-08-07
US20140256774A1 (en) 2014-09-11
EP2731597C0 (en) 2023-12-20
KR20140050661A (ko) 2014-04-29
KR20190069607A (ko) 2019-06-19
EP2731597A2 (en) 2014-05-21
JP2014524918A (ja) 2014-09-25
US20250214939A1 (en) 2025-07-03
WO2013010034A2 (en) 2013-01-17
CA2844150C (en) 2019-09-03
HUE065757T2 (hu) 2024-06-28
EP2731597B1 (en) 2023-12-20
US20210261508A1 (en) 2021-08-26
EP2731597A4 (en) 2015-04-08
CA2844150A1 (en) 2013-01-17

Similar Documents

Publication Publication Date Title
PL2731597T3 (pl) Sposoby leczenia stanu zapalnego i nadciśnienia tętniczego za pomocą wychwytywaczy gamma-ketoaldehydowych
EP2768443A4 (en) METHODS AND DEVICES FOR TREATING HYPERTENSION
EP2717931A4 (en) ASSOCIATIONS AND RELATED METHODS
PL2696754T3 (pl) Urządzenie i sposób pomiaru stresu
IL228212A (en) Methods and instruments for a functional layer with a power layer
EP2736330A4 (en) COMPOUNDS AND METHODS
IL230917A (en) 1dyrk inhibitors and their uses
EP2747560A4 (en) CONNECTIONS AND METHODS
EP2736332A4 (en) CONNECTIONS AND METHODS
GB201122195D0 (en) Composition and method
PT2663864T (pt) Método de avaliação de imunodiversidade e seu uso
IL234829A0 (en) Methods and preparations for treating inflammation
EP2736329A4 (en) COMPOUNDS AND METHODS
GB201408236D0 (en) Composition and method
GB201110783D0 (en) Methods and uses
EP2744275A4 (en) METHOD AND DEVICE FOR SAVING ENERGY
ZA201306848B (en) Transverse driven-roller belt and convetor
GB201122089D0 (en) Telecomunication apparatus and methods
EP2755363A4 (en) METHOD AND DEVICE FOR FAST DATA DISTRIBUTION
IL260077A (en) Methods of treating excess bilirubin in the blood with stanoporfin
GB201112981D0 (en) An arrangement and method
GB201116774D0 (en) Uses and methods
GB201101862D0 (en) Method and device
GB201106433D0 (en) Composition and method
ZA201308807B (en) Hypertension and hyperuricemia